RIL
ABCL icon

Rothschild Investment LLC’s AbCellera Biologics ABCL Stock Holding History

Rothschild Investment LLC’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
14,895
+400
+3% +$1.96K ﹤0.01% 1000
2026
Q1 		$50.6K Hold
14,495
– – ﹤0.01% 1110
2025
Q4 		$49.6K Sell
14,495
-1,320
-8% -$5.89K ﹤0.01% 1021
2025
Q3 		$79.5K Buy
+15,815
New +$69.7K ﹤0.01% 862
2023
Q3 		– Sell
-23,500
Closed -$152K – 479
2023
Q2 		$152K Sell
23,500
-6,800
-22% -$46.4K 0.01% 463
2023
Q1 		$228K Sell
30,300
-4,800
-14% -$43.6K 0.02% 428
2022
Q4 		$356K Sell
35,100
-6,600
-16% -$76.2K 0.03% 343
2022
Q3 		$412K Buy
41,700
+8,700
+26% +$95.5K 0.04% 306
2022
Q2 		$351K Hold
33,000
– – 0.03% 349
2022
Q1 		$322K Buy
33,000
+7,000
+27% +$66.3K 0.03% 383
2021
Q4 		$372K Buy
+26,000
New +$395K 0.03% 371

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Rothschild Investment LLC's ABCL Position: Q2 2026 in Review

Rothschild Investment LLC increased its AbCellera Biologics (ABCL) stake by 2.8% in Q2 2026, buying an estimated $1.96K and bringing the position to 14,895 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Rothschild Investment LLC first reported a position in ABCL in Q4 2021 and has held it in 11 quarters since. The position peaked at $412K in Q3 2022. 62 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Rothschild Investment LLC held 14,895 shares of AbCellera Biologics worth $117K as of Q2 2026.
  • Rothschild Investment LLC bought 400 AbCellera Biologics shares in Q2 2026, an estimated $1.96K.
  • AbCellera Biologics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1000 holding.
  • Rothschild Investment LLC first reported a position in AbCellera Biologics in Q4 2021 and has held it in 11 quarters since.
  • Rothschild Investment LLC's AbCellera Biologics position peaked at $412K in Q3 2022.
  • 62 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.